Exagen

Exagen ROA

The Return on Assets (ROA) of Exagen (XGN) as of Nov 7, 2026 is -34.39 %. In the previous year, Return on Assets (ROA) was -33.82 % — a change of 1.66% (lower).

ROA

-34.39 %

YoY

1.66%

Last updated:

In 2025, Exagen's return on assets (ROA) was -34.39 %, a 1.66% increase from the -33.82 % ROA in the previous year.

The Exagen ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-27.74 USD
Jan 1, 2019
-13.63 USD
Jan 1, 2020
-21.29 USD
Jan 1, 2021
-21.75 USD
Jan 1, 2022
-54.96 USD
Jan 1, 2023
-41.60 USD
Jan 1, 2024
-33.82 USD
Jan 1, 2025
-34.39 USD
The Exagen ROA history
YEARROAYoY
-34.39 %+1.66%
-33.82 %-18.70%
-41.60 %-24.31%
-54.96 %+152.67%
-21.75 %+2.16%
-21.29 %+56.19%
-13.63 %-50.85%
-27.74 %-77.94%
-125.70 %-4.15%
-131.15 %+50.13%
-87.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Exagen Stock analysis

What does Exagen do? Exagen Inc is a leading company in the development and marketing of diagnostic tests and precision medicine products. The company was founded in 2001 and is headquartered in Albuquerque, New Mexico, USA. Exagen aims to improve the diagnosis and treatment of autoimmune diseases such as lupus, rheumatism, and similar conditions. The company's history dates back to the discovery of a molecular biomarker associated with rheumatoid arthritis. Based on this biomarker, Exagen developed a diagnostic test called Vectra DA, which determines disease activity in patients with rheumatoid arthritis. The Vectra DA test is the world's first diagnostic test to use this biomarker to determine rheumatism activity with higher accuracy. It was approved by the FDA in 2010 and has since become an important test in the diagnosis and treatment of rheumatism. Exagen has since expanded its business activities to other autoimmune diseases, including systemic lupus erythematosus (SLE) and Sjögren's syndrome. The company offers a range of diagnostic tests, including the AVISE SLE test, AVISE Sjögren's syndrome test, and AVISE lupus test. These tests are designed to increase accuracy in the diagnosis and treatment of autoimmune diseases. The tests are based on a combination of biomarkers specifically selected for each disease. Exagen's tests are used by physicians, clinics, and hospitals to diagnose, monitor, and treat autoimmune diseases. Additionally, the company is also utilized by medical researchers, pharmaceutical companies, and biotechnology companies to support their research and development of therapies against autoimmune diseases. An important aspect of Exagen's business model is collaboration with health insurance companies and healthcare systems. The company works closely with these partners to ensure that its tests are covered by insurance and that patients have access to the best treatment options. In recent years, the company has experienced rapid growth, with a revenue growth of 273% between 2018 and 2020. Exagen's growth has been driven by the introduction of new tests and expansion into new markets. In 2019, the company opened a branch in Germany and expanded its offerings to include the use of digital technologies to support the diagnosis and treatment of autoimmune diseases. Exagen's product portfolio also includes products that support patients in monitoring their autoimmune diseases. This includes the MyRA app and MyRA monitor, which provide real-time information about the health status of rheumatism patients. The app was developed to assist patients in documenting symptoms and monitoring their therapeutic progress. Exagen is an innovative company that aims to improve the diagnosis and treatment of autoimmune diseases. With its advanced diagnostic tests and precision medicine products, the company has already made a significant contribution to healthcare and will continue to play an important role in the future. Exagen is one of the most popular companies on Eulerpool.

ROA Details

Understanding Exagen's Return on Assets (ROA)

Exagen's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Exagen's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Exagen's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Exagen’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Exagen stock

Return on Assets (ROA) of Exagen is -34.39 % in 2025.

Return on Assets (ROA) of Exagen changed from -33.82 % to -34.39 %, representing a 1.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Exagen since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Exagen with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Exagen

All Key Metrics — Exagen